Audentes Therapeutics, Inc. (BOLD) Receives Average Recommendation of “Hold” from Brokerages
Audentes Therapeutics, Inc. (NASDAQ:BOLD) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $22.25.
A number of brokerages recently weighed in on BOLD. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Evercore ISI began coverage on shares of Audentes Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Wedbush reissued an “ourperform” rating and issued a $20.00 price target on shares of Audentes Therapeutics in a report on Monday, May 15th.
Shares of Audentes Therapeutics (NASDAQ BOLD) opened at 22.63 on Friday. Audentes Therapeutics has a 52 week low of $13.13 and a 52 week high of $23.00. The firm has a 50-day moving average of $20.15 and a 200-day moving average of $17.33. The firm’s market cap is $628.75 million.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, analysts expect that Audentes Therapeutics will post ($3.53) EPS for the current year.
In other news, CEO Matthew R. Patterson sold 2,850 shares of the company’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Louis G. Lange sold 15,000 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $19.78, for a total value of $296,700.00. Following the sale, the director now owns 470,799 shares in the company, valued at $9,312,404.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,850 shares of company stock worth $1,025,220. Company insiders own 47.30% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in BOLD. Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. Nationwide Fund Advisors increased its position in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. Citadel Advisors LLC bought a new stake in shares of Audentes Therapeutics during the first quarter valued at about $184,000. State of Wisconsin Investment Board bought a new stake in shares of Audentes Therapeutics during the second quarter valued at about $210,000. Finally, Rhumbline Advisers bought a new stake in shares of Audentes Therapeutics during the second quarter valued at about $252,000. Hedge funds and other institutional investors own 77.01% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.